Kim Gun-Jik, Lee Jae-Ho, Lee Deok Heon
Department of Thoracic and Cardiovascular Surgery, Kyungpook National University Hospital, Kyungpook National University School of Medicine Department of Anatomy, Keimyung University School of Medicine, Dongsan Medical Center, Daegu, Republic of Korea.
Medicine (Baltimore). 2017 Jan;96(3):e5413. doi: 10.1097/MD.0000000000005413.
Recently, an association between Merkel cell polyomavirus (MCPyV) and epidermal growth factor receptor (EGFR) mutations in nonsmall cell lung cancer (NSCLC) was reported. However, the underlying carcinogenic effects and the prognosis related to MCPyV are still unclear. The aim of this study was to clarify the incidence and prognosis related to MCPyV infections in NSCLC.Tissue samples from 167 NSCLC patients (92 with squamous cell carcinomas [SCCs] and 75 with adenocarcinomas) were analyzed for the presence of MCPyV and EGFR mutations. Clinicopathological characteristics, disease-free survival rate, and overall survival rate were assessed with respect to MCPyV.MCPyV DNA was detected in 30 patients (18.0%) out of 167 patients, and EGFR mutations were found in 31 out of 127 patients (24.4%). EGFR mutations were more frequently detected in MCPyV-positive patients than in MCPyV-negative patients; however, this did not reach statistical significance (P = 0.075). There was no difference in overall survival between patients with and without MCPyV infections. The disease-free survival rate of patients with pN0 stage, SCC, or EGFR mutations was lower for patients with MCPyV than without MCPyV (P = 0.036, 0.042, and 0.050, respectively).Although the prevalence of MCPyV infection was relatively low, the presence of MCPyV DNA was significantly correlated with cancer prognosis in subgroups of NSCLC patients. These results suggest that MCPyV may be partly associated with pathogenesis and prognosis in some cases of NSCLC.
最近，有报道称默克尔细胞多瘤病毒（MCPyV）与非小细胞肺癌（NSCLC）中的表皮生长因子受体（EGFR）突变之间存在关联。然而，MCPyV潜在的致癌作用以及与预后的关系仍不清楚。本研究的目的是阐明NSCLC中与MCPyV感染相关的发病率和预后。对167例NSCLC患者（其中92例为鳞状细胞癌[SCC]，75例为腺癌）的组织样本进行分析，以检测MCPyV和EGFR突变的存在情况。针对MCPyV评估临床病理特征、无病生存率和总生存率。167例患者中有30例（18.0%）检测到MCPyV DNA，127例患者中有31例（24.4%）发现EGFR突变。MCPyV阳性患者中EGFR突变的检出频率高于MCPyV阴性患者；然而，这未达到统计学显著性（P = 0.075）。MCPyV感染患者与未感染患者的总生存率无差异。MCPyV阳性患者的pN0期、SCC或EGFR突变患者的无病生存率低于MCPyV阴性患者（分别为P = 0.036、0.042和0.050）。尽管MCPyV感染的患病率相对较低，但MCPyV DNA的存在与NSCLC患者亚组的癌症预后显著相关。这些结果表明，在某些NSCLC病例中，MCPyV可能部分与发病机制和预后相关。
